Differences in Biologic Drug Effects and Distal Particulate Embolization in Three Paclitaxel-Coated Balloons for Femoropopliteal Lesions in a Rabbit Model.
Marie YoshikawaSho ToriiKazuki AiharaMasatoshi ItoNorihito NakamuraSatoshi NodaAyako YoshikawaSayo UtsunomiyaGaku Nakazawa MdYuji IkariPublished in: Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2023)
These findings suggest that Ranger demonstrates the strongest paclitaxel effect, as well as the second-best effect regarding distal particulate embolization, making it a good treatment option for patients with peripheral artery disease among the 3 DCBs evaluated in the current study. Further clinical head-to-head comparisons with larger numbers of patients are needed to explore which DCB is the most effective and safe treatment option.Clinical Impact:The findings of the current preclinical study suggests that Ranger demonstrates the strongest paclitaxel effect, as well as the second-best effect regarding distal particulate embolization making it a good treatment for patients with intermittent claudication and chronic limb-threatening ischemia.